BioAtla Investor Presentation Deck

Phase 1 CAB-CTLA-4 (BA3071): Meaningful Clinical Benefit at 350 mg in Combination with PD1 Confirmed Partial and Complete Responses Overall Response to date Complete Response Partial Response Stable Disease Progressive Disease bicatla Data Cut Date: 15Nov23 N=5 1 1 1 2 Change in Target Lesion from baseline (%) 40- 20 -20 -40 -60 -80 -100 Uveal melanoma (PD) 5 NSCLC (PD-non-target/new lesion) 10 Time (Weeks) Uveal melanoma (SD) Gastro-esophageal (confirmed PR, post data cut) 15 20 Cervical (CR) 25 BioAtla| Overview 18

View entire presentation